Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-11

Clinical Trial Update: Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat [Phase 3]

View source ↗

Summary

Phase 3 double-blind trial assessing efficacy and tolerance of Ambroxol 20 mg lozenges for sore throat (pharyngitis) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambroxol lozenges 20 mg (ambroxol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pharyngitis | Phase 3 | Status: COMPLETED | Results posted: 2019-07-11